GlassScriptPhysician profile
Leah Stambaugh
NPI 1275145047
$2,326.39
in general payments reported to CMS, 2019-2025
21 companies · $628 in 2025
The $628 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $747 · 2024: $776 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $392.03 | 2022-2024 | Zeposia |
| Abbvie INC. | $386.46 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.04 | 2022-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $200.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $186.71 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.55 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $110.02 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $102.86 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Aimmune Therapeutics, INC. | $99.76 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $83.35 | 2023 | Compliance Endokit |
| Genzyme Corporation | $67.62 | 2023-2025 | |
| Organon LLC | $60.17 | 2023-2024 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $55.26 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $40.94 | 2022-2024 | Suflave |
| Merck Sharp & Dohme LLC | $33.80 | 2024 | Dificid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $28.90 | 2024 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $25.06 | 2025 | Voquezna |
| Pfizer INC. | $17.95 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.45 | 2023 | |
| Intercept Pharmaceuticals, INC. | $16.16 | 2024 | |
| Ardelyx, INC. | $14.28 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Stambaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.